4.35
Precedente Chiudi:
$4.43
Aprire:
$4.42
Volume 24 ore:
48,391
Relative Volume:
0.42
Capitalizzazione di mercato:
$37.58M
Reddito:
$140.46M
Utile/perdita netta:
$-146.34M
Rapporto P/E:
-3.4252
EPS:
-1.27
Flusso di cassa netto:
$-117.73M
1 W Prestazione:
+12.99%
1M Prestazione:
-3.12%
6M Prestazione:
-58.57%
1 anno Prestazione:
-69.80%
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Nome
Karyopharm Therapeutics Inc
Settore
Industria
Telefono
617-658-0600
Indirizzo
85 WELLS AVENUE, NEWTON, MA
Confronta KPTI con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
KPTI
Karyopharm Therapeutics Inc
|
4.35 | 41.99M | 140.46M | -146.34M | -117.73M | -1.27 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
2025-07-11 | Ripresa | H.C. Wainwright | Buy |
2023-01-19 | Iniziato | Piper Sandler | Overweight |
2022-11-04 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2022-02-09 | Aggiornamento | JP Morgan | Underweight → Neutral |
2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
2021-08-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2021-08-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2020-07-02 | Iniziato | Morgan Stanley | Overweight |
2020-03-04 | Iniziato | Barclays | Overweight |
2020-01-17 | Downgrade | Wedbush | Outperform → Neutral |
2019-07-23 | Aggiornamento | JP Morgan | Neutral → Overweight |
2019-07-05 | Reiterato | H.C. Wainwright | Buy |
2019-07-05 | Reiterato | Robert W. Baird | Outperform |
2019-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
2019-02-28 | Reiterato | BofA/Merrill | Underperform |
2019-02-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
2019-01-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
2018-12-03 | Iniziato | B. Riley FBR | Buy |
2018-11-09 | Aggiornamento | Wedbush | Neutral → Outperform |
2018-05-24 | Downgrade | Wedbush | Outperform → Neutral |
2018-04-02 | Ripresa | Leerink Partners | Outperform |
2017-11-15 | Ripresa | H.C. Wainwright | Buy |
2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
2016-09-08 | Reiterato | H.C. Wainwright | Buy |
2016-08-30 | Aggiornamento | Jefferies | Hold → Buy |
2016-08-18 | Iniziato | H.C. Wainwright | Buy |
2016-06-28 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
What drives Karyopharm Therapeutics Inc. stock priceConsistently high returns - PrintWeekIndia
Karyopharm Therapeutics Inc. Stock Analysis and ForecastFast-track wealth growth - PrintWeekIndia
What analysts say about Karyopharm Therapeutics Inc. stockUnprecedented market success - Autocar Professional
How high can Karyopharm Therapeutics Inc. stock price go in 2025High-yield market plays - jammulinksnews.com
Triple Refractory Multiple Myeloma Market Forecast 2032: - openPR.com
Is Karyopharm Therapeutics Inc. a good long term investmentRapid wealth multiplication - jammulinksnews.com
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Will Karyopharm Therapeutics Inc. stock split in the near futureHigh Return Intraday Picks - Newser
HC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI) - MSN
H.C. Wainwright downgrades Karyopharm stock to Neutral amid financial concerns - Investing.com Canada
Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com
How Karyopharm Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser
What makes Karyopharm Therapeutics Inc. stock price move sharplyROI Driven Alerts - beatles.ru
Why Karyopharm Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Expert Consultation - Newser
Newton biotech cuts over 50 jobs, and other biotech news - The Business Journals
HC Wainwright Initiates Coverage on Karyopharm Therapeutics (NASDAQ:KPTI) - Defense World
Karyopharm Therapeutics: A Liquidity Crossroads with Little Room to Pivot - AInvest
Karyopharm stock tumbles after disclosing failed financing talks By Investing.com - Investing.com South Africa
Karyopharm Shares Slide After Financing Efforts Stall, Strategic Review Underway - MSN
Karyopharm's Freefall: What's Driving the Collapse? - AInvest
Karyopharm Therapeutics Inc Azioni (KPTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Karyopharm Therapeutics Inc Azioni (KPTI) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Paulson Richard A. | President and CEO |
May 06 '25 |
Sale |
7.12 |
236 |
1,680 |
82,503 |
Rangwala Reshma | EVP & Chief Medical Officer |
Apr 23 '25 |
Sale |
6.17 |
419 |
2,585 |
28,853 |
Paulson Richard A. | President and CEO |
Apr 04 '25 |
Sale |
3.74 |
245 |
916 |
82,739 |
Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Mar 04 '25 |
Sale |
6.29 |
3,445 |
21,669 |
34,314 |
Paulson Richard A. | President and CEO |
Mar 04 '25 |
Sale |
6.29 |
11,694 |
73,555 |
82,984 |
Rangwala Reshma | EVP & Chief Medical Officer |
Mar 04 '25 |
Sale |
6.29 |
3,587 |
22,562 |
29,272 |
Poulton Stuart | EVP, Chief Development Officer |
Mar 04 '25 |
Sale |
6.29 |
3,548 |
22,317 |
27,414 |
Mano Michael | SVP, General Counsel&Secretary |
Mar 04 '25 |
Sale |
6.29 |
2,793 |
17,568 |
21,047 |
Poulton Stuart | EVP, Chief Development Officer |
Feb 18 '25 |
Sale |
0.63 |
5,914 |
3,726 |
320,714 |
Paulson Richard A. | President and CEO |
Feb 04 '25 |
Sale |
0.65 |
4,099 |
2,664 |
1,120,158 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):